Color
code:
Privately held
Publicly traded (stock ticker symbol)
Acquired, subsidiary, nonprofit, or dissolved
(therefore not counted as a separate genomics firm)
Note: This table is usually updated weekly or biweekly, but is undergoing a major update and will not be revised regularly until sometime in October 2002
Updated 27 August 2002
*Patents in DNA Patent Database (www.genomic.org) through Dec 31, 1999 (in all cases), or when entry updated (see final column).
For listing by public v. private ownership and country of origin (this file updated to 10 June 2001)
| |
Firm Name |
Website |
Public or private? |
Address1 |
Address2 |
City |
State |
PostalCode |
Country |
Phone |
Fax |
PrimaryContact |
|
Founding year |
Firm Type |
Patents* |
Special terms for patent search |
Other Comments |
Date entry modified |
||
|
|
Qiagen Genomics |
Subsidiary of Qiagen |
1725 220th Street SE |
Suite 104 |
Bothell |
WA |
98021 |
|
425-398-3140 |
425-398-3150 |
Andreas Dusterhoft, Director R&D Genomic Services |
6 |
Patents for Qiagen GmbH (parent company) |
||||||||
|
|
PPD Discovery |
Subsidiary of PPD Inc (PPDI) |
1505 B. O’Brien Dr. |
Menlo Park |
CA |
94025 |
|
650.617.2033 |
650.617.9574 |
Fred Eshelman, CEO |
0 |
Susidiary of PPD, Inc. |
|||||||||
|
|
MDS Proteomics Inc |
Subsidiary of MDS Corp. |
75 Internatoinal Boulevard |
Toronto |
M9W6L6 |
|
416-213-4194 or 800-382-4124 |
416-213-4199 |
Ian Lennox, President and CEO of Drug Discovery and Development Sector |
0 |
Subsidiary of MDS Corp; formed new CRO 3/01 |
||||||||||
|
|
Callida Genomics Inc. |
Subsidiary of Hyseq; collaboration with Affymetrix |
George Rathman, Interim President and CEO |
2001 |
INSTRMT, DNASEQ |
Assigned Hyseq sequence-by-hybridization patents; see Hyseq. Owned 90% Hyseq, 10% Affymetrix. |
8aug02 |
||||||||||||||
| 5. |
RNAture |
Subsidiary of Hitachi |
1003 Health Sciences Road West |
Irvine |
CA |
92612-3054 |
|
877-327-8762 949-725-2743 |
949-725-2788 |
Masato Mitsuhashi, President and CEO |
0 |
Wholly owned subsidiary of Hitachi Chemical |
|||||||||
|
|
Expression Analysis |
Subsidiary of Analytical Sciences Inc. |
2605 Meridian Parkway |
Suite 200 |
Durham |
NC |
27713 |
|
(919) 544-8500 |
(919) 544-7507 |
Laura Reid, chief of genomic sciences |
0 |
|||||||||
|
|
Toyobo Tsuruga Gene Analysis Laboratory |
Subsidiary |
10-24, Toyo-cho |
Tsuruga |
914-0047 |
|
81-770-22-7643 |
81-770-22-7671 |
0 |
Genetic testing and contract sequencing; subsidiary of Toyoba |
|||||||||||
|
|
Arradial Inc. |
Started by Alexion, a publicly traded firm |
Boston |
MA |
|
617-241-5794 |
P. Thomas Vogel, President and CEO |
2000 |
0 |
Started by Alexion Pharmaceuticals |
|||||||||||
| 9. |
EXACT Sciences Corp |
Publicly tranded (EXAS) |
63 Great Road |
Maynard |
MA |
01754 |
|
978-897-2800 |
978-897-3481 |
Don M. Hardison, President and CEO |
7 |
10 patents listed as of February 2000; formerly Exact Laboratories, Inc.; IPO Feb 2001 |
|||||||||
|
|
Pharsight Corp. |
Publicly traded; subsidiary NASDAQ: PHST |
11230 Sorrento Valley Road |
Suite 140 |
San Diego |
CA |
02121 |
|
858-625-1343 650-314-3889 Mtn View |
858-597-1353 |
Janice H. Kurth, VP Genomics |
2000 |
0 |
Pharsight mainly a clinical research management firm; genomics branch started 2000 |
|||||||
|
|
LJL Biosystems Inc. |
Publicly traded, now part of Molecular Devices (MDCC) |
404 Tasman Drive |
Sunnyvale |
CA |
94089 |
|
(888)611-4555 |
(408)541-8786 |
Lev Leytes, Chairman, President and CEO |
0 |
Acquired by Molecular Devices Corp. July 2000 |
|||||||||
|
|
CRS Robotics Corp. |
Publicly traded on Toronto SE (ROB) |
5344 John Lucas Drive |
Burlington |
Ontario |
L7L 6A6 |
|
(905) 332-2000 800-365-7587 |
(905) 332-1114 |
Ralph Steedman, President and CEO |
0 |
||||||||||
|
|
Inex Pharmaceuticals |
Publicly traded on Toronto Exchange (IEX) |
100-8900 Glenlyon Parkway |
Glenlyon Business Park |
Burnaby |
BC |
V5J 5J* |
|
604-419-3200 |
604-419-3201 |
David J. Main, President and CEO |
2 |
|||||||||
|
|
Life Technologies Inc. |
Publicly traded on OTC (acquired) |
PO Box 6482 |
Rockville |
MD |
20849-6482 |
|
301-840-8000 |
301-670-1394 |
J. Stark Thompson, President and CEO |
58 |
Being acquired by Invitrogen; deal to be complete in 2000. |
|||||||||
|
|
Genetic Vectors Inc. |
Publicly traded on OTC (GVEC) |
5201 NW 77th Avenue |
Suite 100 |
Miami |
FL |
33166 |
|
305-716-0000 |
305-716-0001 |
Mead McCabe, Jr., CEO |
0 |
Acquired DNA Sciences, Inc (of San Diego, different from DNA Sciences, Inc above) 2/2000 |
||||||||
|
|
GeneScan Europe AG |
Publicly traded on Neuer Market (GEP) |
Engesserstr. 4 b |
79108 |
Freiburg |
|
0761-5038-0 |
0761-5038-111 |
Ulrich Birsner, CEO |
0 |
12 subsidiary companies; no DPD patents for BioChip, GeneScan, or BioRobotics, but refers to a “large patent portfolio at its disposal” and several pending patents on its website. 2000 annual report states 23 patents for 2000, none by 1999. |
||||||||||
|
|
MorphoSys GmbH |
Publicly traded on Neuer exchange (MOR) |
Lena-Christ-Straße 48 |
D- 82152 |
Martinsreid/Munich |
|
49 (0)89 89927 0 |
49 (0)89 89927 222 |
Simon E. Moroney, CEO |
1 |
|||||||||||
|
|
Oxford GlycoSciences plc |
Publicly traded on London Exchange (OGSI; OGS) |
2 The Quadrant, Barton Lane |
Abingdon Science Park |
Abingdon |
Oxon |
OX16 3J |
|
(44)1235-543200 |
(44)1235-554701 |
David Ebsworth, CEO |
5 |
(Patents for Oxford gene systems =3, Oxford technologies 1, Oxford biomedica 1; See also ISIS Innovation with 7 patents) |
||||||||
|
|
Pharmagene PLC |
Publicly traded on London Exchange (PGN) |
Orchard Road |
Royston |
Hertfordshire |
SG8 5HD |
|
44 0-1763 211 600 |
44-1-1763-211 630 |
Alastair Riddell, CEO |
0 |
IPO 7/2000 |
|||||||||
|
|
Molecular Devices Corp. |
Publicly traded NASDAQ: (MDCC) |
1311 Orleans Drive |
Sunnyvale |
CA |
94089 |
|
800-635-5577 |
Joseph D. Keegan, President and CEO |
2000 |
0 |
Merger of LJL BioSystems July 2000 |
|||||||||
|
|
Zymogenetics |
Publicly traded (ZGEN) |
1201 Eastlake Avenue East |
Seattle |
WA |
98102-3702 |
|
206-442-6600 |
206-442-6608 |
Bruce L. A. Carter, President and CEO |
80 |
Established as US discovery arm of Novo Nordisk;separate company 2000, IPO Feb 2002 |
|||||||||
|
|
Valentis Inc. |
Publicly traded (VLTS) |
863A Mitten Road |
Burlingame |
CA |
94010 |
|
650.697.1900 |
650.652.1990 |
Banjamin F. McGraw, President and CEO |
Ben@valentis.com CEO |
4 |
Website lists 58 Issued US patents 2/15/01 |
Formed from merger of PolyMASC, GeneMedicine, and Megabios |
|||||||
|
|
Sigma Genysys |
Publicly traded (subsidiary, not included in R&D or market cap figures) |
1442 Lake Front Circle |
The Woodlands |
TX |
77380 |
|
800-234-5DNA |
281-363-2693 |
0 |
Subsidiary of Sigma Aldrich {not included among publicly traded genomics firms due to small fraction of genomics business) |
||||||||||
|
|
Sangamo Biosciences Inc. |
Publicly traded (SGMO) |
501 Canal Boulevard |
Richmond |
CA |
94804 |
|
510-970-6000 |
510-236-8951 |
Edward O. Lanphier, President and CEO |
0 |
Acquired Gendaq June 2001 |
|||||||||
|
|
Rosetta Inpharmatics |
Publicly traded (RSTA). Acquired by Merck (not included in figures and tables) |
12040-115th Avenue NE |
Kirkland |
WA |
98034 |
|
425-820-8900 |
425-821-5354 |
Stephen Friend, President and CSO |
1 |
IPO August 8, 2000; Acquisition by Merck & Co. announced May 11, 2001. |
|||||||||
|
|
Paradigm Genetics |
Publicly traded (PDGM) |
104 Alexander Drive, Building 2 |
PO Box 14528 |
Research Triangle Park |
NC |
27709-4528 |
|
919-425-3000 |
919-544-8094 |
Heinrich Gugger, President and CEO |
1997 |
GENEFNL, GENEXPR, AGRIVET |
2 |
27jul02 |
||||||
| 27. |
Pharmacopeia |
Publicly traded (PCOP) |
3000 Eastpark Boulevard |
Cranbury |
NJ |
08512 |
|
609 452 3600 |
609 452 3672 |
Joseph A. Mollica, President and CEO |
4 |
Owns Accelrys, which acquired Synomics June 2001; acquired Eos Aug 2001. |
|||||||||
|
|
Genetix |
Publicly traded (GTX.L) on FTSE |
Queensway |
New Milton |
Hampshire |
BH25 5NN |
|
01-425-624-600 |
01-425-624700 |
Mark Reid, CEO |
0 |
Acquired Genpak Ltd. IPO November 2000 |
|||||||||
|
|
Ecopia Biosciences Inc. |
Publicly traded (EIA TorontoSE) |
7290 Frederick-Banting |
Saint-Laurent |
Québec |
|
(514) 336-2700 |
(514) 336-8827 |
Eric A. Cohen, Chairman and CEO |
0 |
|||||||||||
| 30. |
Epoch Biosciences |
Publicly traded (EBIO) |
21720 - 23rd Dr. SE |
Suite 150 |
Bothell |
WA |
98021 |
|
425.482.5555 |
425.482.5550 |
Bill Gerber, CEO |
10 |
Includes patents for Epoch Pharmaceuticals, Bothell and Redmond, WA |
||||||||
| 31. |
AVI BioPharma |
Publicly traded (AVII; AVIIW; AVIIZ) |
One SW Columbia Street |
Suite 1105 |
Portland |
OR |
97258 |
|
503-227-0554 |
503-227-0751 |
Denis R. Burger, CEO |
1 |
Assigned to AntiVirals Inc. (former name) Also licensed 11 patents from Ohio State Univ, 16 from Univ Nebraska |
||||||||
|
|
Autogen Limited |
Publicly traded (ATG Australian Stock Exchange) |
210 Kings Way |
South Melbourne |
Victoria |
3205 |
|
61 3 9234 1188 03 9234 1188 or 0419 897 501 |
61 3 9234 1198 |
Greg Collier, Chief Scientific Officer |
0 |
||||||||||
|
|
Array BioPharma |
Publicly traded (ARRY) |
1885 33rd Street |
Boulder |
CO |
80301 |
|
303-381-6600 |
303-449-5376 |
Robert E. Conway, CEO |
0 |
IPO Nov 2000 |
|||||||||
|
|
Genetic Technologies Ltd. |
Publicly traded (GTG ASX) |
60-66 Hanover Street |
Fitzfory |
Victoria |
3065 |
|
3.9415.1135 |
3.9417.2987 |
Mervyn Jacobson, Executive Chairman |
5 |
Acquired
GeneType AG (Zug, |
|||||||||
| 35. |
Chondrogene Inc. |
Publicly traded (YDG on Canadian Venture Exchange) |
800 Petrolia Road |
Unit No. 15 |
Toronto |
Ontario |
|
(416) 650-0060 |
(416) 650-0055 |
David E Caspari, President and CEO |
0 |
||||||||||
|
|
Genomics One Corporation |
Publicly traded on Montreal Eschange (GNX) |
3030 Le Carrefour Blvd. |
Suite 902 |
Laval |
Quebec |
H7T 2P5 |
|
(877)684-3637 (450)688-4499 |
Dr. Suzanne Lebel, President |
0 |
||||||||||
|
|
SignalGene Inc. |
Publicly traded (SGI) |
8475 Christophe-Colomb Avenue |
Suite 1000 |
Montreal |
Quebec |
H2M 2N9 |
|
(514)850-2400 |
(514)850-2424 |
George Masters, Interim President and CEO |
0 |
|||||||||
|
|
Tm Bioscience Corp. |
Publicly traded (CDNX: TMC) |
439 University Ave. |
11th Floor |
Toronto |
Ontario |
|
(416) 593-4323 |
(416) 593-1066 |
Gregory C. Hines, President & CEO |
0 |
||||||||||
| 39. |
Azign Bioscience A/S |
Publicly traded NeuroSearch AS (NEUS.CO) |
Vestre Teglgade 10 |
Copenhagen |
DK-2450 |
|
45 70 22 22 02 |
45 70 23 23 04 |
0 |
Formed with merger of NeuroSearch AS acquisition of Display Systems Biotech AS |
|||||||||||
|
|
LION BioScience AG |
Publicly traded ( |
Im Neuenheimer Feld 517 |
Heidelberg |
D 69120 |
|
49-6221-403-823 |
49-6221-403-835 |
Friedrich von Bohlen, CEO |
0 |
IPO July 10, 2000 |
||||||||||
|
|
deCODE Genetics |
Publicly traded (DCGN) |
Lynghalsi 1 |
Rekjavik |
IS-100 |
|
354-577-1900 |
354-577-1901 |
Kari Stefansson, President and CEO |
0 |
MediChem also |
IPO July 2000; acquired MediChem March 2002 |
|||||||||
|
|
Keryx Biopharmaceuticals Inc. |
Publicly traded (KERX) |
Kiryat Mada 5 |
Har Hotzvim |
Jerusalem |
91326 |
|
972-2-541-2700 |
972-2-541-2701 |
Morris Laster, CEO |
0 |
IPO June 2000 |
|||||||||
|
|
Biacore AB |
Publicly traded (BCOR) |
Radsgatan |
SE-754 50 |
Uppsala |
|
46 18 675700 |
46 18 150110 |
Ulf Jonsson, President |
2 |
|||||||||||
|
|
Pyrosequencing AB |
Publicly traded (PYRO A: Stockholm) |
SE-752 |
Uppsala |
28 |
|
46-18-565-900 |
46-18-516000 |
Erik Wallden, President and CEO |
0 |
|||||||||||
|
|
Cytomyx |
Publicly traded (EPIC-CYX) on AIM |
140 Science Park |
Cambridge |
CB4 0GF |
|
44-1223-508191 |
44-1223-508198 |
0 |
Formerly Cambridge BioScience |
|||||||||||
|
|
Gemini Genomics Ltd. |
Publicly traded (GMNI) being acquired by Sequenom |
162 Science Park |
Cambridge |
CB4 0GH |
|
44-0-1223-435300 44 1223 435339 |
44-0-1223-435301 |
Paul Kelly, CEO |
2 |
IPO July 2000; announced acquisition by Sequenom May 2001 completed Q3 2001. |
||||||||||
|
|
Abgenix |
Publicly traded (ABGX) |
7601 Dumbarton Circle |
Fremont |
CA |
94555 |
|
(510)608-6500 |
(510)608-6589 |
R. Scott Greer, Chairman, President and CEO; Raymond Withy to become CEO mid-2002 |
4 |
||||||||||
|
|
Aclara Biosciences Inc. |
Publicly traded (ACLA) |
1288 Pear Avenue |
Mountain View |
CA |
94034 |
|
650-210-1200 |
Joseph M. Limber, President and CEO |
0 |
|||||||||||
|
|
Affymetrix Inc. |
Publicly traded (AFFX) |
3380 Central Expressway |
Santa Clara |
CA |
95051 |
|
(408)731-5000 |
(408)481-0422 |
Stephen Fodor, CEO |
25 |
||||||||||
|
|
Applied Biosystems |
Publicly traded (ABI) |
850 Lincoln Centre Drive |
Foster City |
CA |
94404 |
|
650-638-5800 800-345-5224 |
650-638-5884 |
Michael Hunkapiller, President |
27 |
Includes PerSeptive Biosystems patents (4);, Boston Probes; PNA Diagnostics |
Name reverted to Applied Biosystems July 2000 (was PE Biosystems 1997-2000) |
||||||||
|
|
Applied Molecular Evolution Inc. |
Publicly traded (AMEV) |
3520 Dunhill Street |
San Diego |
CA |
92121 |
|
858-597-4990 |
858-597-4950 |
William D. Huse |
6 |
Formerly Ixsys (includes Ixsys patents) |
IPO July 2000 |
||||||||
|
|
ARIAD Pharmaceuticals Inc. |
Publicly traded (ARIA) |
26 Landsdowne Street |
Cambridge |
MA |
02139 |
|
(617)494-0400 |
(617)494-8144 |
Harvey J. Berger, Chairman and CEO |
1 |
||||||||||
|
|
Aurora Biosciences Corp. |
Publicly traded (ABSC). Acquired by Vertex. |
11010 Torreyana Road |
San Diego |
CA |
92121 |
|
(619)404-6600 |
(619)404-6714 |
Michael Wokasch, President, Chairman, and CEO |
5 |
3 for Aurora; 2 for PanVera, which was acquired by Aurora in Feb 2001 |
Aurora acquired by Vertex July 2001 |
||||||||
|
|
AxyS Pharmaceuticals Inc. |
Publicly traded | |||||||||||||||||||